Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
about
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis opticaTreatment of primary Sjögren syndrome.Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.Deletional tolerance prevents AQP4-directed autoimmunity in mice.What's new in neuromyelitis optica? A short review for the clinical neurologist.Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders.Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder.Monitoring B-cell repopulation after depletion therapy in neurologic patients.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
P2860
Q26748601-C4A67D30-728A-4C9B-A12C-B611EA1A001FQ30249011-A3A03BFC-2603-45F7-9784-3E18A8D9BF44Q36359371-F240DB50-18F8-4419-8361-1C6CED8FBAE1Q36484465-8B28AC4C-068D-468A-A9E9-21674AC9EE7CQ37620483-DE5E6B08-1DAF-4B80-9ED4-A478515B6C25Q37712394-74DA34C9-30F9-4954-A7CB-F9447132E6C1Q39176987-72A904B9-3387-4D92-BF2A-C87A0D119988Q39692977-9683A54E-5A4D-4048-836A-ECA1395E3B89Q47555447-EED0F798-59C5-480D-8E59-4C87FA56D1D4Q47827665-CDDF30C1-992F-4697-8F2B-A2B9D8CB0DEBQ48198452-BCCD1ECF-E543-4804-9CAF-F2029A847695Q53125112-51D62554-1674-4210-8404-7A6D2CEEBC97Q54982151-6663C617-95D2-477B-8263-96B591055B4CQ55283551-CFF535FE-74FC-4DA3-9D74-EE8C25C53F16Q58573155-61C26FE5-187A-497A-AE54-062D4B131184
P2860
Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Neuromyelitis optica spectrum ...... tuximab in Caucasian patients.
@en
type
label
Neuromyelitis optica spectrum ...... tuximab in Caucasian patients.
@en
prefLabel
Neuromyelitis optica spectrum ...... tuximab in Caucasian patients.
@en
P2093
P2860
P356
P1476
Neuromyelitis optica spectrum ...... tuximab in Caucasian patients.
@en
P2093
F Sangalli
M Radaelli
M Rodegher
V Barcella
V Martinelli
P2860
P304
P356
10.1177/1352458515594042
P577
2015-07-21T00:00:00Z